Robert Mendelson, MD
Cardiovascular Disease · Jamaica, NYNPI 1215997267
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.9%), food and beverage and education — rather than concentrated in one kind of arrangement. Janssen Research & Development, LLC accounts for 88.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $970 and has fallen 98.3% since, to $16 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NY, where the typical reported total is $1,486.
Across 18 payments — averaging $60.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$970
- GE HealthCare$67
- Merck$22
- Kiniksa Pharmaceuticals International, PLC$19
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16
Across 53 payments — averaging $4353.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$140K
- Novartis$90K
- Eli Lilly$656
What the payments were for
- Travel & lodging$62357%
- Food & beverage$45041%
- Education$222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 13 | $970 |
| GE HealthCare | 2 | $67 |
| Merck | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
How this compares
$1,094 in reported general payments places this provider in the 40th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $77,635 |
| XareltoRivaroxaban | 60 | $76,434 |
| JardianceEmpagliflozin | 40 | $41,320 |
| Praluent PenAlirocumab | 13 | $6,465 |
| Ranolazine ErRanolazine | 37 | $6,061 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 74 | $4,754 |
| Carvedilol ErCarvedilol Phosphate | 23 | $4,049 |
| Metoprolol Succinate | 155 | $2,917 |
| Valsartan | 57 | $1,694 |
| Candesartan Cilexetil | 22 | $1,617 |
| Verapamil ErVerapamil Hcl | 62 | $1,488 |
| Nifedipine ErNifedipine | 59 | $1,373 |
| ClopidogrelClopidogrel Bisulfate | 66 | $1,120 |
| Atorvastatin Calcium | 86 | $1,088 |
| Ramipril | 58 | $1,047 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Jamaica
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.